Arbutus Biopharma Corp

NASDAQ:ABUS   3:59:55 PM EDT
3.07
-0.24 (-7.25%)
4:55:04 PM EDT: $3.08 +0.01 (+0.33%)
Products, Strategic Combinations

Arbutus And Qilu Pharmaceutical Enter Licensing Agreement For AB-729

Published: 12/13/2021 13:15 GMT
Arbutus Biopharma Corp (ABUS) - Arbutus and Qilu Pharmaceutical Enter Into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize Ab-729 in Mainland China, Hong Kong, Macau and Taiwan.
Arbutus Biopharma Corp - to Receive $40 Million in Upfront Payment.
Arbutus Biopharma - in Addition, Qilu Will Make $15 Million Equity Investment in Arbutus Common Shares at a Price of $4.19 per Share.
Arbutus Biopharma - to Receive Up to $245 Million in Development & Commercialization Milestone Payments, Double-digit Tiered Royalties, $15 Million Equity Investment.
Arbutus Biopharma- Qilu to Be Responsible for Funding All Development and Commercialization Activities for Mainland China, Hong Kong, Macau & Taiwan.